Metabolic/Obesity Phase 3 Deal Benchmarks (2026)

Median upfront of $1.2B with total deal values reaching $5.7B.

Median Upfront

$1.2B

Total Deal Value

$4.6B

Royalty Range

18.5%–30%

Territory Multiplier

Understanding Metabolic/Obesity Deal Benchmarks at Phase 3

Phase 3 Metabolic/Obesity licensing deals command a median upfront payment of $1.2B, with values ranging from $801M at the low end to $1.6B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the metabolic/obesity therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $3.4B to $5.7B, with a median of $4.6B. Royalty rates for metabolic/obesity assets at this stage typically fall between 18.5% and 30% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

Year	Licensor	Licensee	Upfront	Total Value	Deal Type
2021	Dicerna Pharmaceuticals	Novo Nordisk	$3.3B	$3.3B	acquisition
2024	Scribe Therapeutics	Novo Nordisk	$55M	$1.6B	licensing
2024	MBX Biosciences	Novo Nordisk	$40M	$610M	licensing
2024	Amgen	N/A (internal)	$0M	$1.9B	collaboration
2024	Boehringer Ingelheim	Zealand Pharma	$100M	$1.8B	licensing
2023	Structure Therapeutics	Roche	$150M	$3.7B	licensing
2024	Catalent	Novo Holdings	$16.5B	$16.5B	acquisition
2022	Pliant Therapeutics	Novartis	$60M	$490M	collaboration

PRO

See All Comparable Deals

View 8 comparable Metabolic/Obesity transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Phase 3 Metabolic/Obesity deals?

The median upfront payment for Phase 3 Metabolic/Obesity licensing deals is $1.2B, based on our analysis of comparable transactions. Values range from $801M for early-stage or less differentiated assets up to $1.6B for premium programs with strong clinical data or first-in-class mechanisms.

How does Global territory affect Metabolic/Obesity deal value?

Global rights carry a 1x multiplier relative to base deal economics. This means global metabolic/obesity deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Phase 3 Metabolic/Obesity licensing?

Royalty rates for Phase 3 metabolic/obesity assets typically range from 18.5% to 30% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$77M upfront

Metabolic/Obesity · Preclinical · Global

$229M upfront

Metabolic/Obesity · Phase 1 · Global

$589M upfront

Metabolic/Obesity · Phase 2 · Global

$3.5B upfront

Metabolic/Obesity · Approved · Global

$721M upfront

Oncology · Phase 3 · Global

$515M upfront

Neurology/CNS · Phase 3 · Global

$901M upfront

Immunology · Phase 3 · Global

$678M upfront

Metabolic/Obesity · Phase 3 · US Only

Explore More

All Metabolic/Obesity Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Metabolic/Obesity · Phase 3

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Metabolic/Obesity Phase 3 Deal Benchmarks (2026). Retrieved from https://calculator.ambrosiaventures.co/data/metabolic-phase-3-deals-global

HTML

<a href="https://calculator.ambrosiaventures.co/data/metabolic-phase-3-deals-global">Metabolic/Obesity Phase 3 Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$801M	$1.2B	$1.6B
Total Deal Value	$3.4B	$4.6B	$5.7B
Royalty Rate	18.5%	—	30%